Recombinant interferon-α2B efficacy in complex therapy of pneumonia in premature newborns

A prospective randomized study of clinical efficacy of recombinant interferon-α2b in combination with vitamins E and C (VIFERON®) in the complex treatment of congenital and postnatal pneumonia was conducted in 60 premature infants of gestational age from 29 to 34 weeks. In addition to the standard antibacterial, infusion, and metabolic therapy, children of the main group (30 patients) received 150 000 IU of the drug 3 times a day for 10 days. Patients in the control group comparable in gestational age and clinical status (30 children) received only standard therapy. The study revealed that inclusion of the drug in the complex therapy contributes to a more rapid improvement of the clinical condition, the cure of infectious toxicosis and respiratory failure, especially significant by the 5th day of therapy, contributes to a more rapid elimination of pneumonic infiltration according to lungs radiography, reduces hospital stay. © 2019, Pediatria Ltd.. All rights reserved.

Авторы
Degtyareva E.A. 1, 2 , Kufa M.A. 1, 2 , Kantemirova M.G. 1 , Nikopolskya A.V.2 , Bragina E.M.2 , Shcherbakova M.U. 1 , Malinovskya V.V.3 , Shuvalov A.N.3
Номер выпуска
4
Язык
Русский
Страницы
172-178
Статус
Опубликовано
Том
98
Год
2019
Организации
  • 1 Medical Institute, Peoples’ Friendship University of Russia, Moscow, Russian Federation
  • 2 Children’s Infectious Diseases Hospital №.6, Moscow, Russian Federation
  • 3 Federal Scientific Research Center of Epidemiology and Microbiology named after N.F. Gamalei, Moscow, Russian Federation
Ключевые слова
Congenital and postnatal pneumonia; Immunomodulating therapy; Premature infants; Recombinant interferon-α2b; Treatment
Дата создания
24.12.2019
Дата изменения
24.12.2019
Постоянная ссылка
https://repository.rudn.ru/ru/records/article/record/55180/